Stay updated on Monalizumab & Cetuximab in Head & Neck Cancer Clinical Trial

Sign up to get notified when there's something new on the Monalizumab & Cetuximab in Head & Neck Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Monalizumab & Cetuximab in Head & Neck Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the safety evaluation of escalating doses of Monalizumab given IV in combination with cetuximab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck. This change may reflect new information on the antitumor activity of the treatment regimen with or without anti-PD(L)1.
    Difference
    0.1%
    Check dated 2024-06-06T14:27:12.000Z thumbnail image
  7. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying age, health conditions, and prior treatments required for inclusion in the study. Previously, this section did not provide any information.
    Difference
    22%
    Check dated 2024-05-22T21:29:20.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:49:04.000Z thumbnail image

Stay in the know with updates to Monalizumab & Cetuximab in Head & Neck Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Monalizumab & Cetuximab in Head & Neck Cancer Clinical Trial page.